83 results
Key updates in valvular heart disease management: insights from the 2025 ESC/EACTS Guidelines
03 Sep 2025
Alex Sticchi provides his take on the new ESC Valvular Guidelines presented at the ESC Congress 2025 in Madrid.
Author
Surgical left atrial appendage occlusion in VHD without AF: OPINION Trial
03 Sep 2025
Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.
Author
TOP-CABG: the timing of platelet inhibition after coronary artery bypass grafting trial
02 Sep 2025
Jonathan Curio provides his take on TOP-CABG, presented by Xin Yuan at ESC Congress 2025 in Madrid.
Author
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
03 Sep 2025
Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.
Author
TARGET-FIRST: Early aspirin discontinuation after PCI in low-risk acute MI patients
01 Sep 2025
Elad Asher provides his take on the results of TARGET-FIRST presented by Giuseppe Tarantini at the ESC Congress 2025 in Madrid.
Author
TAILORED-CHIP: Tailored antiplatelet therapy for complex high-risk PCI
29 Aug 2025
Nicola Ryan provides her take on the results of TAILORED-CHIP presented by Duk-Woo Park at the ESC Congress 2025 in Madrid.
Author
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
02 Sep 2025
Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...
Author
OPTION-STEMI: Immediate versus staged complete revascularisation during index admission in patients with STEMI and multivessel disease
02 Sep 2025
Mirvat Alasnag provides her take on OPTION-STEMI, presented by Youngkeun Ahn at ESC Congress 2025 in Madrid.
Author
Duration of DAPT in ACS: The DUAL-ACS Trial
31 Aug 2025
Ali Nazmi Calik interviews David Newby on the landmark DUAL-ACS trial results he presented at ESC Congress 2025 in Madrid.
The trial compared 3 months versus 12 months of dual antiplatelet therapy (DAPT) after myocardial infarction in an all-comer population. Findings suggest that shorter therapy may offer better...
Author
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/whats-new-on-pcronline/2025/esc/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)